An Early Success

The example outlined demonstrates an early success of the Resonant platform prior to full platform scale-up, where dozens of equal or greater caliber candidates have been generated. Although only a couple of hundred clones were generated in this early run, among these was the high-value candidate RT-00001. This antibody targets a protein specifically expressed in the tumor microenvironment, highly efficacious as a single agent therapeutic, and would not have been discovered by industry standard screening methods.

Microenvironment Specific Effects

RT-00001 is therapeutically active against physiological tumor cells, but not in standard 2D cultures. The target for RT-00001 has been overlooked by standard industry approaches before.

Resonant System



Note the distinctive epithelial-mesenchymal (EMT) physiology in Resonant microenvironment conditions. RT-00001 treatment induces formation of apoptotic bodies.

Standard Industry Approach



Treatment does not affect 2D cultured cells.

Specific Expression in the Tumor State

Tumor tissue biopsy specimens from pancreatic, melanoma, breast, colon, and brain tumors demonstrate widespread RT-00001 target overexpression in these cancer types. Normal tissues from these same sites show little to no RT-00001 staining.

normal breast

breast cancer

normal colon

colorectal cancer

normal pancreas

pancreatic cancer

normal brain

brain cancer

normal skin


RT-00001 Dramatically Reduces Metastasis

RT-00001 significantly inhibits MDA-MB-231 metastasis and growth in an in vivo mouse model. Luciferase expressing MDA-MB-231 cells were injected into the left ventricle of nude mice and treated with control ab or RT-00001 twice weekly for 4 weeks.

Efficacy in Patient-Derived Tumors

Model 1: Human triple-negative breast cancer PDX MC-1. Tumors implanted and allowed to establish contacts and vasculature for 7 days prior to initiation of treatment. No signs of toxicity or distress in RT-00001-treated animals.

Model 2: Human triple-negative breast cancer PDX UM-1. This model is relatively slow-growing. Tumor implantation and treatment schedule as at left. No signs of toxicity or distress in RT-00001-treated animals.